| Grant ID | DP240239 |
| Awarded On | May 15, 2024 |
| Title | Development of LILRB4 antibodies and companion precision biomarkers for patient selection to overcome myeloid-dependent resistance to T cell checkpoint therapy |
| Program | Product Development Research |
| Award Mechanism | Seed Awards for Product Development Research |
| Institution/Organization | Bectas Therapeutics Inc. |
| Principal Investigator/Program Director | Ronan O'Hagan |
| Cancer Sites | Kidney and Renal Pelvis, Lung and Bronchus, Skin |
| Contracted Amount |
$2,750,000* *Pending contract negotiation |
| Lay Summary |
Despite the promise of immune-based therapies for cancer 75% - 85% of patients are not cured by existing immune therapies. Limited progress has been made in addressing the lack of response in patients who do not benefit from existing therapies. This is due largely to a lack of precise understanding of which patients will benefit from which additional therapy. We have identified myeloid cell surface receptors, including the LILRB4 protein, that suppress the immune system and drive resistance to existing therapy in 25% of patients. We have also identified a biomarker that enables precise identification of the cancer patients who will benefit from inhibition of LILRB4. We have generated a high-... |